FRED UPTON, MICHIGAN
CHAIRMAN

HENRY A. WAXMAN, CALIFORNIA
RANKING MEMBER

ONE HUNDRED THIRTEENTH CONGRESS

# Congress of the United States

## House of Representatives

COMMITTEE ON ENERGY AND COMMERCE
2125 RAYBURN HOUSE OFFICE BUILDING
WASHINGTON, DC 20515–6115
Majority (202) 225–2927
Minority (202) 225–3641

May 24, 2013

Dr. Janet Woodcock
Director
Center for Drug Evaluation and Research
U.S. Food and Drug Administration
10903 New Hampshire Avenue
Silver Spring, MD 20993

Dear Dr. Woodcock:

Thank you for appearing before the Subcommittee on Health on Thursday, April 25, 2013, to testify at the hearing entitled "Securing Our Nation's Prescription Drug Supply Chain."

Pursuant to the Rules of the Committee on Energy and Commerce, the hearing record remains open for ten business days to permit Members to submit additional questions for the record, which are attached. The format of your responses to these questions should be as follows: (1) the name of the Member whose question you are addressing, (2) the complete text of the question you are addressing in bold, and (3) your answer to that question in plain text.

To facilitate the printing of the hearing record, please respond to these questions by the close of business on Monday, June 10, 2013. Your responses should be e-mailed to the Legislative Clerk in Word format at Sydne.Harwick@mail.house.gov and mailed to Sydne Harwick, Legislative Clerk, Committee on Energy and Commerce, 2125 Rayburn House Office Building, Washington, D.C. 20515.

Thank you again for your time and effort preparing and delivering testimony before the Subcommittee.

Sincerely,

Joseph R. Pitts
Chairman
Subcommittee on Health

cc: The Honorable Frank Pallone, Jr., Ranking Member, Subcommittee on Health

Attachment

## Additional Questions for the Record

### The Honorable Renee Ellmers

1. Dr. Woodcock, you mention that a breach in any point of the supply chain could lead to dangerous outcomes for patients. How critical is identifying and licensing all entities that manufacture, store, transport and distribute drugs in realizing visibility and security in the supply chain? And can you elaborate why?

2. We all know that the most important goal of pharmaceutical supply chain track and trace legislation is to ensure that medicines are safely delivered to patients in North Carolina and the rest of the country. In the wake of recent high profile prescription drug counterfeiting cases in the U.S., can you share with us a summary of the discussions that you have had with patient groups regarding the importance of supply chain safety to combat these types of cases from occurring in the future?